Marken Opens Logistics Hub in Chicago
By

By
Marken has opened a new operational hub in Chicago, Illinois that joins Marken’s existing New York, Boston, and Philadelphia locations. The new location is Marken’s sixth facility in the US,…

Sun Pharma to Buy Russian Pharma Company
By

By
Sun Pharma, a Mumbai, India-based pharmaceutical company, has entered a definitive agreement to acquire 85.1% of JSC Biosintez, a Russian pharmaceutical company, in a deal worth $60 million. The transaction…

Catalent Acquires OTC Softgel Company
By

By
Catalent has agreed to acquire Accucaps Industries Limited, an Ontario, Canada-based developer and manufacturer of over-the-counter (OTC), high potency, and conventional pharmaceutical softgels. Financial details of the transaction were not disclosed.…

West Completes Facility Expansion
By

By
West Pharmaceutical Services, an Exton, Pennsylvania-headquartered manufacturer of packaging components and delivery systems for injectable drugs and healthcare products, has completed a 60,000-square-foot expansion at its contract manufacturing facility near…

AstraZeneca, Eisai, GlaxoSmithKline, and Janssen Lead Pipeline News
By

By
A roundup of the latest market developments from the pipelines of the pharmaceutical majors and other related news, featuring news from AstraZeneca, Eisai, GlaxoSmithKline, and Janssen. Editor’s Note: This article…

Allergan, Janssen, Novo Nordisk, and Sanofi Lead Drug Approvals
By

By
A roundup of the latest drug approvals, including from the pharmaceutical majors, featuring news from Allergan, Janssen, Novo Nordisk, and Sanofi. Editor’s Note: This article is updated on a continuous basis…

Amgen, Allergan Seek Approval for Avastin Biosimilar
By

By
Amgen and Allergan have submitted a biologics license application to the US Food and Drug Administration (FDA) for ABP 215, a biosimilar candidate to Avastin (bevacizumab), Roche’s anti-cancer biologic. ABP…

AstraZeneca, Allergan Complete Pact for Crohn’s Disease Drug
By

By
AstraZeneca has completed the licensing agreement between MedImmune, its global biologics research and development arm, and Allergan, for the global rights to MEDI2070, a biologic candidate being developed for Crohn’s…

Novartis Buys Selexys in $665-Million Deal
By

By
Novartis has acquired Selexys Pharmaceuticals, an Oklahoma City, Oklahoma-based company specializing in therapeutics for hematologic and inflammatory disorders. Novartis exercised its right to acquire Selexys following favorable results of a…

BMS in Immuno-Oncology Pact for Microbiomes
By

By
Bristol-Myers Squibb (BMS) and Enterome, a Paris-based company that develops pharmaceuticals and diagnostics based on the gut microbiome, have formed an immuno-oncology-focused collaboration for the discovery and development of microbiome-derived…